All News

Ctexli is the first FDA-approved treatment for adults with cerebrotendinous xanthomatosis.

Semaglutide has been in shortage since 2022 due to increased demand.

Physician with expertise in pain research discussed emerging technologies in the future of pain medicine and how they must be adapted to improve patient outcomes.

Measles is highly contagious, and the Texas Department of State Health Services said that additional cases are likely to occur in Gaines County, which had 57 cases as of February 21, 2025.

Experts gathered to explore the pathophysiology and therapeutic management of burn injury-induced pain.

Tirzepatide (Mounjaro, Zepbound), a glucagon-like peptide-1 (GLP-1) medication, demonstrates improved diabetes control and decreases in insulin requirements.

A program that includes peer coaching and monitoring tools can help pharmacists better manage hypertension in patients.

Researchers conducted a literature review to explore topics in entrepreneurship that impact pharmacy practice and education.

A recent metanalysis found that patients with type 1 diabetes had a 50% higher chance of developing dementia.

A conversation with Ginger Lemay, PharmD, Jeffrey Bratberg, PharmD, and Audrey Whalen, PharmD.

Researchers measured current pharmacy practices and the future potential of practices geared toward reducing instances of opioid overdose.

Researchers conducted a survey of community pharmacists to understand their use, concerns, and opportunities regarding ChatGPT technology in their practice setting.

The FDA also granted priority review, with a Prescription Drug User Fee Act target action date of August 19, 2025.

ASC30, an investigational glucagon-like 1-peptide receptor agonist, demonstrates mean weight reductions from baseline of 4.3% and 6.3% for 2 separate cohorts.

A PDUFA target action date for the PrEP therapy has been set for June 19, 2025.

Patients with musculoskeletal pain were treated with cryotherapy spray to assess its use in providing immediate and sustained pain relief.

How pharmacies will pay for the Medicare Drug Price Negotiation Program

The FDA initially approved deucravacitinib (Sotyktu) in September 2022 to treat moderate-to-severe plaque psoriasis.

Explore key legislative actions changing pharmacy practice in 2025 and beyond.

Patients prescribed high-dose opioids were given the option to switch to buprenorphine in hopes of improving pain and reducing opioid dosage.

Previously, dupilumab (Dupixent) received orphan drug designation for bullous pemphigoid.

The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access to drugs that the organization had reviewed for cost effectiveness in 2022.

Researchers investigate the effects of subanesthetic doses of esketamine for the treatment of pain and cognition in patients undergoing surgery.

The vaccine is the first virus-like particle single-dose vaccine for chikungunya for patients 12 years and older.

Among a diverse cohort of patients with type 2 diabetes (T2D), researchers examined the use of automated insulin delivery for lowering hemoglobin A1c levels.

Denosumab-dssb is approved as a 60 mg pre-filled syringe as a biosimilar for Prolia and 120 mg vial as a biosimilar for Xgeva.

The combination includes 2 previously approved vaccines to target the 5 major serogroups of Neisseria meningitidis.

In order to meet national targets, the United States should expand vaccination administration in complementary sites like pharmacies.